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Background: Coronary artery disease remains the principal cause of death in patients with diabetes mellitus.
Diabetic mice display exacerbated injury following myocardial ischemia-reperfusion (MI/R) and are resistant to most
therapeutic interventions. We have reported that sodium sulfide (Na2S) therapy confers cardioprotection during
MI/R in non-diabetic mice. Here we tested the hypothesis that Na2S therapy would limit the extent of myocardial
injury following MI/R when administered at the time of reperfusion.
Methods and results: Diabetic mice (db/db, 12 weeks of age) were subjected to transient myocardial ischemia for
a period of 30 minutes followed by reperfusion up to 24 hours. Na2S (0.05 to 1 mg/kg) or saline (vehicle) was
administered into the left ventricular lumen at the time of reperfusion. Na2S therapy significantly decreased
myocardial injury in the db/db diabetic mouse, as evidenced by a reduction in infarct size and circulating troponin-I
levels. The reduction in myocardial injury was also associated with a reduction in oxidative stress and a decrease
in cleaved caspase-3 expression. In an effort to evaluate the signaling mechanism responsible for the observed
cardioprotection, additional groups of mice were sacrificed during early reperfusion. Hearts were excised and
processed for Western blot analysis. These studies revealed that Na2S therapy activated the Erk1/2 arm of the
Reperfusion Injury Salvage Kinase (RISK) pathway.
Conclusion: These findings provide important information that myocardial Erk1/2 activation by Na2S therapy
following MI/R sets into motion events, which ultimately lead to cardioprotection in the setting of diabetes.
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Diabetes mellitus is a disease of metabolic dysregulation
characterized by abnormal glucose metabolism [1]. It is
associated with a number of long-term complications as-
sociated with a decreased quality of life and reduced life
expectancy including nephropathy, retinopathy, stroke
and cardiovascular disease. For instance, patients with
Type 2 diabetes mellitus (T2DM) have up to a 4-fold in-
creased risk of developing coronary heart disease com-
pared to non-diabetic patients. Moreover, patients with* Correspondence: jcalver@emory.edu
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unless otherwise stated.T2DM have a higher risk of mortality following myocar-
dial ischemia compared with non-diabetics [2] due in
part to an increased size of myocardial infarction [3].
Therefore, it is critically important to develop and im-
plement therapeutic strategies that will attenuate myo-
cardial infarct size in T2DM patients. However, limited
basic science research has been performed in the field of
acute myocardial infarction in diabetic models as the
large majority of research studies investigating myocar-
dial ischemia-reperfusion (MI/R) injury have focused on
otherwise healthy animals. Moreover, of the studies that
have investigated the pathophysiology of MI/R injury in
diabetes the majority have predominately used Type 1
diabetic models. This is an important observation givenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[4]. As such, there is a paucity of research investigating
the mechanisms of increased myocardial infarction in the
setting of T2DM.
Hydrogen sulfide (H2S) is an endogenously produced
gaseous signaling molecule that is critical for the regulation
of cardiovascular homeostasis [5,6]. It is produced enzy-
matically in mammalian species via the action of three
enzymes in the cysteine biosynthesis pathway: cystathionine-
γ-lyase (CSE), cystathionine-β-synthase (CBS), and 3-
mercaptopyruvate sulfutransferase (3-MST). Over the
last several years, several labs including ours have inves-
tigated the therapeutic potential of H2S. These studies
provide compelling evidence that both exogenous and
endogenous H2S exert cytoprotective effects, especially
against MI/R injury and heart failure [7-14]. These and
other studies demonstrate that H2S utilizes a variety of
effects to counter ischemic injury, including its ability
to attenuate oxidative stress, inhibit apoptosis, and re-
duce inflammation [15]. Together, these findings sug-
gest that therapy targeting endogenous and exogenous
H2S offer cytoprotection against MI/R injury.
Recently, a role for H2S in the etiology of diabetes has
been suggested [16]. More specifically, circulating levels
of H2S are negatively related to diabetes. For instance,
plasma H2S levels decline in response to streptozotocin
[17]. Similarly, plasma H2S levels, as well as the aortic
production of H2S progressively decrease as the diabetic
pathology increases in non-obese diabetic mice [18].
Additionally, we found that lower levels of H2S are not
confined to the circulation in the setting of diabetes, as
evidenced by the findings that cardiac levels of H2S were
also decreased in db/db diabetic mice. On the basis of
this evidence, one can speculate that decreased H2S
levels contribute to the pathophysiology of diabetes [19].
This postulate is further supported by the findings that
restoring H2S levels in the setting of diabetes protects
against myocardial infarction, cardiomyopathy and vas-
cular dysfunction in models of STZ-induced diabetes
[20-22]. Clinically, the negative association between dia-
betes and H2S also exists, as evidenced by the findings
that lower circulating H2S levels are detected in plasma
samples taken from patients with T2DM [16,23]. There-
fore, strategies designed to restore H2S levels have the
potential to be used as adjuvant therapy to provide bene-
ficial effects against the cardiovascular complications
associated with diabetes.
To date, the vast majority of research studies investigat-
ing the cardioprotective effects of H2S in models of acute
MI/R injury have been conducted in non-diabetic animals.
Therefore, the purpose of this study was to determine if
H2S therapy given at the time of reperfusion could provide
cardioprotection in the setting of diabetes using a well-
established in vivo mouse model of MI/R injury.Materials and methods
Animals
Male non-diabetic (C57BLKS/J) and diabetic (BKS.Cg-
Dock7M+/+Leprdb/J mice; Jackson Labs, Bar Harbor, ME)
were utilized at 12 weeks of age. All experimental mouse
procedures were approved by the Institute for Animal
Care and Use Committee at Emory University School of
Medicine and conformed to the Guide for the Care and
Use of Laboratory Animals, published by the National
Institutes of Health (NIH Publication No. 86-23, Revised
1996) and with federal and state regulations.
Materials
Sodium Sulfide (Na2S; Sigma Aldrich. USA; catalog#
407410) was dissolved in saline and administered using a
32-gauge needle at doses ranging from 0.05 to 1 mg/kg
in a final volume of 50 μL as a single injection directly
into the lumen of the left ventricle at the time of reperfu-
sion. Saline was administered in the same manner for
the respective vehicle groups. In all cases, the Na2S was
prepared just prior to use. Groups of mice also received
1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio) buta-
diene (U0126; 0.1 mg/kg).
Blood glucose determination
Blood obtained via a tail snip was screened using a Xtra
glucose-monitoring system (Precision).
Myocardial ischemia-reperfusion protocol and myocardial
injury assessment
Surgical ligation of the left coronary artery (LCA) myo-
cardial infarct size determination, and Troponin-I mea-
surements were performed similar to methods described
previously [9].
Oxidative stress
The degree of lipid peroxidation was determined by
evaluating the levels of malondialdehyde (MDA) in heart
tissue using a commercially available thiobarbituric acid
reactive substances (TBARS) assay kit according to the
manufacture’s instructions (Enzo Life Sciences; catalog#
ALX-850-287-KI01).
Western blot analysis
Samples of the heart were homogenized to obtain whole
cell fractions. Equal amounts of protein were loaded into
lanes of polyacrylamide-SDS gels and Western blot ana-
lysis was performed as previously described [9].
Caspase-3 activity
The activity of Caspase-3 was measured in heart homoge-
nates using a commercially available assay kit according to
the manufacture’s instructions (abcam; catalog# ab39401).
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All data in this study are expressed as mean ± standard
error (SEM). Differences in data between the groups
were compared using Prism 4 (GraphPad Software, Inc)
with Student’s paired 2-tailed t test or one-way analysis
of variance (ANOVA). For the one-way ANOVA, if a
significant variance was found, the Tukey test was used as
the post hoc analysis. A p value less than 0.05 was consid-
ered significant.
Results
Diabetes increases injury following MI/R
Diabetic mice exhibited the typical characteristics of a
severe diabetic phenotype when compared to non-diabetic
mice, including marked obesity and hyperglycemia (Table 1).
In initial studies, non-diabetic and diabetic mice were sub-
jected to 30 minutes of LCA ischemia followed by 4 hours
of reperfusion, at which time the extent of myocardial
infarction was evaluated. Representative mid-ventricular
photomicrographs of hearts from non-diabetic and dia-
betic mice are shown in Figure 1A. Diabetes increased
myocardial infarct size (INF) relative to the area-at-risk
(AAR) by 313% (17.8 ± 3.1 for non-diabetic vs. 73.6 ± 2.9
for diabetic, p < 0.001; Figure 1B).
Na2S dose-dependently reduces injury in diabetic mice
following MI/R
To investigate if exogenous H2S therapy limits MI/R injury
in the setting of diabetes, diabetic mice were subjected to
30 minutes of ischemia and 4 hours of reperfusion. Na2S
(0.05 to 1 mg/kg) or vehicle was administered at the time
of reperfusion via a direct injection into the LV lumen.
Na2S dose-dependently reduced myocardial INF/AAR
(Figure 1C). A dose of 0.1 mg/kg was found to be the most
protective with a 22% reduction in INF/AAR (72.2 ± 2.9
for vehicle vs. 56.0 ± 3.0 for Na2S 0.1 mg/kg, p < 0.01).
Na2S also reduced circulating levels of troponin-I in a dose
dependent manner (Figure 1D). In separate experiments,
additional groups of mice were subjected to 30 minutes of
ischemia and 24 hours of reperfusion. Analogous to theTable 1 Body weights and blood glucose levels
Group n Body weight Blood glucose
(grams) (mg/dL)
Non-diabetic 8 24.3 ± 0.9 154.1 ± 3.1
Diabetic 13 47.1 ± 0.7*** 544.1 ± 19.9***
Diabetic + Na2S (0.05 mg/kg) 8 45.5 ± 1.3*** 531.6 ± 40.9***
Diabetic + Na2S (0.1 mg/kg) 7 46.3 ± 1.2*** 581.1 ± 29.5***
Diabetic + Na2S (0. 5 mg/kg) 5 48.2 ± 1.6*** 536.2 ± 22.8***
Diabetic + Na2S (1 mg/kg) 5 50.2 ± 1.8*** 554.0 ± 34.1***
Diabetic + Na2S (0.1 mg/kg,
24 hr rep)
10 49.9 ± 1.1*** 551.1 ± 36.9***
Values are means ± SEM. ***p < 0.001 vs. Non-Diabetic.earlier findings, mice receiving Na2S (0.1 mg/kg) displayed
a 20% reduction in INF/AAR as compared with vehicle-
treated mice (Figure 1E). Body weight and blood glucose
levels taken prior to ischemia are shown in the Table 1.The reduction in myocardial injury induced by Na2S is
associated with a reduction in apoptosis and oxidative
stress
Further experiments were performed to evaluate the ef-
fects of Na2S therapy on apoptosis and oxidative stress.
For these studies, diabetic mice were subjected to 30 mi-
nutes of myocardial ischemia and 4 hours of reperfusion.
Mice were either treated with Na2S (0.1 mg/kg) or saline
(Veh) at the time of reperfusion. MI/R increased the
expression of cleaved caspase-3, as well as the activity
of caspase-3 in the hearts of Vehicle-treated mice
(Figure 2A-C; p < 0.001 vs. Sham). In contrast the hearts
mice treated with Na2S exhibited a significant reduction
in cleaved caspase-3 expression and caspase-3 activity
compared to Vehicle-treated mice (p < 0.05). Oxidative
stress, as measured by MDA levels, was significantly in-
creased by MI/R (Figure 2D). However, Na2S treated mice
displayed significantly lower levels compared to Vehicle
treated mice (p < 0.01).Na2S Therapy activated the Erk1/2 Arm of the RISK
pathway
Experiments were then conducted to elucidate potential
mechanisms responsible for the cardioprotective effects
of Na2S therapy. For these studies, we focused on com-
ponents of the Reperfusion Injury Salvage Kinase (RISK)
pathway, a signaling cascade involving prosurvival ki-
nases, which confer cardioprotection when specifically
activated at the onset of reperfusion following myocar-
dial ischemia. The concept for the RISK pathway is
based on the evidence that apoptosis contributes to
myocyte cell death following ischemia-reperfusion injury
and that activation of certain kinases exerts anti-
apoptotic effects [24]. Therefore, it has been postulated
that targeting these kinases at the time of reperfusion
with pharmacological agents would protect the myocar-
dium [25]. Our studies first focused on the ability of
Na2S to activate the extracellular regulated kinase 1/2
(Erk1/2) arm of the RISK pathway. For these studies,
diabetic mice were again subjected to 30 minutes of
myocardial ischemia and 4 hours of reperfusion. West-
ern blot analysis of heart homogenates collected from
Sham, Vehicle, and Na2S treated mice revealed that MI/
R did not significantly alter the phosphorylation of Erk1/
2 in the Vehicle-treated mice when compared to Sham
mice (Figure 3A-B). However, treatment with Na2S at
the time of reperfusion significantly increased the phos-
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Figure 1 (See legend on next page.)
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Figure 1 Na2S therapy reduces the extent of myocardial injury in db/db diabetic mice following MI/R. (A) Representative midventricular
photomicrographs of hearts from a non-diabetic mouse and from db/db diabetic mice treated with vehicle or Na2S (0.1 mg/kg) at the time of
reperfusion. (B) Myocardial infarct size relative to the area-at-risk (INF/AAR) in non-diabetic and diabetic mice subjected to 30 minutes of ischemia
followed by 4 hours of reperfusion. (C) Myocardial INF/AAR and (D) circulating troponin-I levels in db/db diabetic mice subjected to 30 minutes
of ischemia followed by 4 hours of reperfusion. For these experiments, mice were treated with vehicle (Veh) or Na2S (0.05 to 1 mg/kg) at the time
of reperfusion. (E) Myocardial INF/AAR in db/db mice subjected to 30 minutes of LCA ischemia and 24 hours of reperfusion. Vehicle or Na2S
(0.1 mg/kg) was administered at the time of reperfusion. Values are mean ± SEM. Numbers inside of the bars indicate the number of animals that
were investigated in each group. *p < 0.05 and **p < 0.01 vs. Vehicle; ***p < 0.001 vs. Vehicle or Non-Diabetic.
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remain unchanged among all groups (Figure 3C).
We then turned our attention to downstream effectors
of the RISK pathway. As with Erk1/2 phosphorylation,
the phosphorylation of p90RSK was only significantly
elevated in the hearts of Na2S treated mice (Figure 3D-E;
p < 0.05 vs. Sham and Vehicle). Total p90RSK remains
unchanged in among all groups (Figure 3F). Next, we eval-
uated the expression of Bcl-xL and the phosphorylation of
Bad, members of the members of the Bcl-2 family of pro-
teins that inhibit and promote apoptosis, respectively. We
chose these members because both are downstream
targets of the RISK pathway. The anti-apoptotic protein
Bcl-xL was found to be significantly reduced in Vehicle-
treated mice compared to Sham (Figure 4A-B; p < 0.05).
In contrast, Na2S treated mice attenuated the reduction in
Bcl-xL levels (p < 0.05 vs. Vehicle). Bad can be phos-
phorylated at Serine residue 112 by p90RSK. Importantly,















































Figure 2 Na2S therapy reduces apoptosis and oxidative stress followi
stress was evaluated in the hearts of db/db diabetic mice subjected to 30
with Na2S (0.1 mg/kg) at the time of reperfusion. (A-B) Representative imm
Caspase-3 Activity. (D) Heart MDA levels. Values are mean ± SEM. *p < 0.05,apoptosis. MI/R significantly reduced the phosphorylation
of Bad in Vehicle-treated mice when compared to Sham
mice (Figure 4A&C; p < 0.05). However, Na2S treatment
prevented this de-phosphorylation (p < 0.05 vs. Vehicle).
Total Bad levels remain unchanged between all groups
(Figure 4A&D).Na2S Therapy inhibited GSK3β
Another downstream target of both Erk1/2 and p90RSK
is Glycogen synthase kinase-3Beta (GSK3β). When GSK3β
is phosphorylated at Tyrosine residue 216 it is activated.
Both Erk1/2 and p90RSK can inhibit GSK3β at this site
via dephosphorylation. MI/R significantly increased the
phosphorylation of GSK3β in Vehicle-treated mice when
compared to Sham mice (Figure 5A-B; p < 0.01). In con-
trast, Na2S therapy attenuated this increase (p < 0.01 vs.
Vehicle). Total GSK3β levels remain unchanged among all
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minutes of ischemia and 4 hours of reperfusion. Mice were treated
unoblots and densitometric analysis of cleaved caspase-3. (C) Cleaved



















































































































































































Figure 3 Na2S therapy activates Erk1/2 signaling following MI/R. (A-C) Representative immunoblots and densitometric analysis of the
expression of phosphorylated Erk1/2 at Threonine-202/Tyrosine-204 residues and total Erk. (D-F) Representative immunoblots and densitometric
analysis of the expression of phosphorylated p90RSK at Threonine residue 359 and total p90RSK. Experiments were conducted with heart homogenates
collected from Sham, Vehicle, and Na2S-treated mice following 30 minutes of ischemia and 4 hours of reperfusion. Values are mean ± SEM. *p < 0.05
and ***p < 0.001 vs. Sham.
Lambert et al. Medical Gas Research 2014, 4:20 Page 6 of 11
http://www.medicalgasresearch.com/content/4/1/20Inhibition of Erk1/2 signaling attenuated the infarct
sparing effects of Na2S therapy
To see if the activation of Erk1/2 was necessary for Na2S
therapy to provide its infarct sparing effects, U0126 was
given alone and in combination with Na2S at the time of
reperfusion. U0126 administration alone did not cause
any further significant increase or decrease in infarct size
compared to Vehicle-treated mice (Figure 6). However
U0126 abolished the infarct sparing effects of Na2S
therapy.
Akt Signaling is not activated by ischemia nor Na2S
therapy
Signaling through the serine/threonine kinase Akt repre-
sents another arm of the RISK pathway. We therefore
sought to determine if Na2S activated Akt signaling in
the diabetic heart. Again, for these studies, mice were
again subjected to 30 minutes of myocardial ischemia
and 4 hours of reperfusion. Western blot analysis of
heart homogenates collected from Sham, Vehicle, and
Na2S treated mice revealed that MI/R did not signifi-
cantly alter the phosphorylation of Akt in the Vehicle-
treated mice when compared to Sham mice (Figure 7).
Our analysis revealed that Na2S therapy also did not
alter the phosphorylation of Akt. Total Akt levels remain
unchanged among all groups.
Discussion
The main findings of this study are the following: 1) Na2S
therapy administered at the time of reperfusion reducesMI/R injury in the setting of T2DM; 2) Na2S therapy acti-
vates the Erk1/2 arm of the RISK pathway; 3) Erk1/2 sig-
naling increases anti-apoptotic proteins and inhibits the
activation of GSK3β 4) Na2S therapy provides it’s infarct
sparing effects in an Erk1/2-dependent manner.
The previous studies investigating the cardioprotective
effects of H2S have provided important mechanistic in-
sights into its cytoprotective actions [15]. However, these
studies have offered very little insights into the ability of
H2S to protect in the setting of a diseased state, such as
diabetes. As such, the results of the current study are
the first to demonstrate that the administration of Na2S
therapy at the time of reperfusion provides cardioprotec-
tion in the setting of T2DM. In agreement with a previ-
ous study with non-diabetic mice [7], we found that
Na2S dose-dependently reduced myocardial injury, as
evidenced by a reduction in infarct size and circulating
troponin-I levels. However, despite the observed cardio-
protective effects of an acute administration of Na2S in
the current study, we found that the magnitude of infarct
size reduction was significantly less than that observed in
non-diabetic mice. This suggests that the underlying path-
ology present in the setting of T2DM may impair critical
cardioprotective signaling and may minimize the thera-
peutic benefit of pharmacological agents. However, these
results are of clinical relevance since they demonstrate
that H2S treatment can potentially be initiated at the time
of coronary artery reperfusion to diabetic patients experi-










































































































































Figure 4 Na2S therapy increases the expression of Bcl-xL and inhibits Bad following MI/R. (A) Representative immunoblots and densitometric
analysis of the expression of (B) Bcl-xL, (C) phosphorylated Bad at Serine residue 112, and (D) total Bad. Experiments were conducted with heart
homogenates collected from Sham, Vehicle, and Na2S-treated mice following 30 minutes of ischemia and 4 hours of reperfusion. Values are
mean ± SEM. *p < 0.05 vs. Sham.
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against MI/R injury is the activation of the RISK pathway.
As noted above, the RISK pathway is a term given to a sig-
naling cascade involving prosurvival kinases, which confer
cardioprotection when specifically activated at the onset



















































Figure 5 Na2S therapy inhibits GSK3β following MI/R. (A) Representati
phosphorylated GSK3β at Tyrosine residue 216, and (C) total GSK3β. Experi
Vehicle, and Na2S-treated mice following 30 minutes of ischemia and 4 homembers reported to be a part of the RISK pathway were
the phosphatidylinositol-3 kinase (PI3K), Akt, and extra-
cellular regulated kinase 1/2 (Erk1/2). Additional studies
have expanded this list to include other kinases such as
protein kinase C (PKC; primarily the PKC-ε isoform),
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Figure 6 Na2S therapy attenuates MI/R injury in an Erk-dependent
manner. Myocardial INF/AAR in diabetic mice subjected to 30 minutes
of ischemia followed by 4 hours of reperfusion. Mice were administered
vehicle, Na2S (0.1 mg/kg), U0126 (0.1 mg/kg), or a combination of U0126











































Figure 7 Na2S therapy did not activate Akt following MI/R. (A) Repres
(B) phosphorylated Akt at Serine residue 473, and (C) total Akt. Experiment
Vehicle, and Na2S-treated mice following 30 minutes of ischemia and 4 ho
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ing the RISK pathway with pharmacological agents may
be a viable treatment option for MI/R injury. For in-
stance, it has now been demonstrated in preclinical
models that insulin, urocortin, atorvastatin, bradykinin,
opioid receptor agonists, atrial natriuretic peptide (ANP),
and Glucagon-Like Peptide-1, reduce myocardial infarct
size when administered at the time of myocardial reperfu-
sion through the activation of the RISK pathway [24].
Importantly, it has also been demonstrated that ANP
reduced infarct size, improved left ventricular function,
and lowered combined end-point of death or cardiac fail-
ure when administered to patients undergoing primary
percutaneous coronary intervention [26].
Mitochondria are essential for cell survival, both be-
cause of their role as metabolic energy producers and as
regulators of programmed cell death [27]. Under normal
conditions, the mitochondrial network of the myocyte
must have properties of both constancy and flexibility,
first providing a steady supply of ATP to fuel contrac-
tion, and second, to adapt the rate of energy production
to meet the changing metabolic demand as workload
varies [28]. The mitochondrial permeability transition
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reperfusion injury because MPTP opening also causes
mitochondrial membrane potential (ΔΨm) depolarization
[28]. Early reperfusion following ischemia represents a
period when ΔΨm is most likely to become unstable due
to the production of high levels of ROS and ensuing oxi-
dative stress. As a result, the loss of ΔΨm during this time
causes a rapid impairment of mitochondrial function,
which ultimately leads to apoptotic cell death through the
release of pro-apoptotic proteins or can initiate necrotic
cell death. Thus, maintaining ΔΨm is of paramount im-
portance during the period of early reperfusion, as it is a
major determinant of cell fate following ischemia [28].
Given, that mitochondria lie at the core of existence of
cellular life, it is of no surprise that they are the most
common effector for numerous cardioprotective-signaling
cascades. Importantly, a common target of the signaling
activated by the RISK pathway is the mitochondria. Specif-
ically, activation of the RISK pathway has been shown to
inhibit the opening of the mPTP [29], thereby preventing
apoptotic death caused by mitochondrial membrane per-
meabilitization [30].
While the downstream effectors of the RISK pathway
have not been fully elucidated, the Erk1/2 signaling arm
has been shown to signal through signal transducer and
activator of transcription 3 (STAT-3), p90RSK, Bcl-2,
Bcl-xL, and HSPs [15,25,31]. Erk1/2 dependent p90Rsk
activation is essential to providing protection against re-
perfusion therapy because active p90RSK phosphorylates
and inhibits the pro-apoptotic protein BAD [32]. This is
important, because when BAD is active it binds to BCL-xL
and disrupts the BCL-xL/Bax complex causing the ac-
cumulation of Bax in the mitochondrial membrane,
which results in apoptosis. Additionally, Erk1/2 dependent
p90Rsk activation also suppresses the opening of the
mPTP by inhibiting GSK3β [33]. It is already known that
the diabetic state impairs the activation of the RISK path-
way in the setting of MI/R. In a type 1 diabetic rat model
(streptozotocin-induced), erythropoietin (EPO)-induced
cardioprotection through RISK signaling was lost [33].
Interestingly in the same study, EPO-induced cardiopro-
tection through RISK signaling was still maintained in
high fat diet (HFD)-induced insulin resistant mice suggest-
ing that it remains unclear how different forms of diabetes
and insulin resistance are affecting the activation of the
RISK pathway in response to MI/R. For this reason alone
it is very important to investigate how the T2DM state
would affect RISK signaling and whether Na2S therapy
would influence the RISK pathway in this model. In our
previous paper we showed that 7 days of Na2S treatment
in a preconditioned state can activate Erk1/2 [20], and be-
cause Erk1/2 is an important part of providing protection
in the early reperfusion state we wanted to see if Na2S
could activate Erk1/2 when it was administered at thetime of reperfusion. The findings of the current study
agree with many others that the diabetic state impairs
the RISK pathway. Specifically, MI/R injury failed to acti-
vate Erk1/2 signaling in untreated mice. This was further
associated with the activation of Bad and GSK3β. Based
on the evidence that MI/R activates Erk1/2 signaling in
non-diabetic animals [34], it can be suggested that im-
paired signaling in the Erk1/2 arm of the RISK pathway
contributes in part to the enhanced injury observed in the
db/db diabetic heart. Importantly, our findings indicate
that Na2S therapy is able to provide protection against
MI/R injury through its ability to activate Erk1/2 signal-
ing during early reperfusion. Moreover, our findings
suggest that the activation of Erk1/2 signaling and subse-
quent activation of p90RSK, inhibition of Bad, and inhib-
ition of GSK3β are responsible for the anti-apoptotic and
infarct lowering effects of Na2S therapy.
Another important finding of the study relates to the
other arm of the RISK pathway: Akt pathway. Specific-
ally, our data suggests that Akt is not activated in the
db/db heart by ischemia-reperfusion injury nor Na2S
therapy. The former is supported by previous data indi-
cating that Akt is not activated by myocardial ischemia
in the db/db heart and likely reflects an impairment in
pro-survival signaling induced by diabetes. The latter is
in contrast to previous findings by our group demon-
strating that H2S therapy activates Akt in the setting of
heart failure [12]. It is important to note that our previ-
ous study used non-diabetic mice and evaluated the acti-
vation of Akt in response to pressure-overload heart
failure. Additionally, we evaluated the activation of Akt
6 weeks after the induction of heart failure. Therefore, it
is possible that Na2S therapy could have an effect on
Akt activation in the db/db heart at a different time
point than the one we evaluated (i.e. 30 minutes of re-
perfusion or 24 hours of reperfusion). As such, future
studies are necessary to determine the role Akt plays in
mediating the cardioprotective effects of H2S therapy in
the setting of type-2 diabetes.
Although the current study demonstrates that a single
administration of Na2S therapy is able to reduce infarction
in the setting of MI/R injury, there are some limitations
that need to be noted. Because a mouse model was used,
these data may not accurately predict human disease.
Therefore, future studies need to be conducted in large
animal models that are more clinically relevant. Another
limitation is that we did not evaluate why T2DM impairs
the RISK pathway during the early reperfusion period
following myocardial ischemia. Future studies are defin-
itely warranted to delve further into the mechanism(s)
responsible for this impairment. Additionally, further
studies are needed to evaluate how Na2S therapy affects
the permeability of the mPTP in the diabetic state fol-
lowing MI/R injury.
Lambert et al. Medical Gas Research 2014, 4:20 Page 10 of 11
http://www.medicalgasresearch.com/content/4/1/20In summary, our findings demonstrate for the first time
that exogenous administration of Na2S attenuates MI/R
injury in diabetic animals when administered at the time
of reperfusion. This is important because it confirms the
potential therapeutic effects of H2S in treating a heart
attack in the setting of diabetes. It also highlights the
complexity of therapeutic intervention for the diabetic
heart following ischemia, as even at its most protective
dose, the robust cardioprotective effects of Na2S that
have previously been reported in the non-diabetic state
were diminished in the diabetic heart.
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